Psychiatry Research - The Consciousness Library

Outcomes of patients receiving interventional psychiatric procedures in a large integrated healthcare system.

Psychiatry Research July 19, 2025 Kevin J Li, Natalie E Slama, Ingrid L Chen et al. 2 citations

Interventional psychiatric procedures (IPPs) such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine intravenous treatments (KIT) are widely used for treatment resistant depression (TRD), but we lack studies of their real-world impact compared to standard outpatient medication management (MM). Longitudinal electronic health records of 22,481 patients in a...

DOI: 10.1016/j.psychres.2025.116647 Full text Esketamine Mdd Major depressive disorder Electroconvulsive therapy +12

Neural basis of GAD improvement following a mindfulness-based intervention and antidepressant treatment: an analysis from a randomized controlled trial.

Psychiatry Research July 12, 2025 Marianna de Abreu Costa, Patrícia Bado, Maiko Schneider et al. 1 citation

The brain mechanisms underlying patient improvement after interventions remain poorly understood. Identifying the shared and distinct neural pathway between improvement mechanisms across distinct treatment modalities might improve our understanding of brain-behavior relationships and inform personalized approaches. To investigate the neural correlations of symptom improvement in Generalized...

DOI: 10.1016/j.psychres.2025.116637 Full text Generalized anxiety disorder Mindfulness Amygdala Antidepressant +1

Online mindfulness-based vs. cognitive-behavioural stress reduction for medical students: A randomized controlled trial.

Psychiatry Research July 11, 2025 Aysegul Yay-Pence, Selcuk Aslan, Merve Coldur et al. 2 citations

This study evaluated the effects of Mindfulness-based stress reduction(MBSR) and cognitive behavioural stress reduction(CBSR) on depression, anxiety, and perceived stress in medical students. A total of 323 medical students studying in Ankara, Turkey, applied to participate and were assessed using the Mini International Neuropsychiatric Interview. Medical students with a psychotic disorder,...

DOI: 10.1016/j.psychres.2025.116632 Full text Mindfulness Cognitive behavioural therapy Mental health Primary prevention +1

Efficacy and Safety of LSD in the treatment of mental and substance use disorders: A systematic review of randomized controlled trials.

Psychiatry Research July 5, 2025 Maria Helha Fernandes-Nascimento, Priscila Weber, André Brooking Negrão 4 citations

LSD (lysergic Acid Diethylamide), a psychedelic compound, has been investigated in recent studies for the treatment of mental disorders. We analyzed the efficacy and safety of LSD in the treatment of mental disorders and substance use disorders in adult patients. We searched Embase, PubMed, Scopus, PsycINFO, the Cochrane Library, CENTRAL, BVS, EBSCO, Epistemonikos, and the grey literature for...

DOI: 10.1016/j.psychres.2025.116622 Full text LSD Lysergic acid diethylamide Psychedelics Substance use disorders +1

A systematic review on the role of EEG and fMRI-Neurofeedback training in the treatment of substance use disorders and behavioral addiction.

Psychiatry Research July 1, 2025 Mazyar Fathi, Mohammad Navid Ebrahimi, Mohammad Banazadeh et al. 6 citations

Neurofeedback (NF), a form of biofeedback, is used to enhance the self-regulation of brain functions by assessing brain activity and delivering feedback signals to ameliorate emotional attributes, cognitive functions, and behaviors. Despite the potential role of NF in substance use disorder (SUD) treatment, a number of gaps such as variations in NF methods persist. This study aims to address...

DOI: 10.1016/j.psychres.2025.116474 Full text Behavioral addiction Substance use disorders FMRI Fnirs, craving +8

Can ketamine and other glutamate receptor modulators be considered entactogens?

Psychiatry Research July 1, 2025 Hiroe Hu, Alaina N Tillman, Miyu Fujita et al. 2 citations

Subanesthetic-dose ketamine has recently been reported to improve hedonic pleasures associated with social interactions and altruism in individuals with treatment-resistant depression. However, whether ketamine-among other glutamate receptor modulators-also improves empathy and/or prosocial behavior in humans remains unknown. Under a framework grounded in neurobiology that proposes that...

DOI: 10.1016/j.psychres.2025.116513 Full text Ketamine Entactogen Glutamate receptor modulators Prosocial behavior +7

Effectiveness of mindfulness based interventions in reducing depressive symptoms across mental disorders: A meta-analysis of randomized controlled trials.

Psychiatry Research June 1, 2025 Ekin Alkan, Geetanjali Kumar, Shreya Ravichandran et al. 11 citations

Mindfulness based interventions (MBIs) are increasingly recognised for their efficacy in treating depressive disorders. Depressive symptoms are prevalent across various disorders and can significantly impact outcomes, therefore being an important transdiagnostic target. Multiple randomized controlled Trials (RCTs) have explored this question in discrete disorders; however, evidence has never...

DOI: 10.1016/j.psychres.2025.116473 Full text Depressive symptoms Mindfulness-based treatments Psychiatric disorders Transdiagnostic

The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.

Psychiatry Research June 1, 2025 Jeremy Weleff, Alejandra Pulido-Saavedra, Ardavan Mohammad Aghaei et al. 4 citations

Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor...

DOI: 10.1016/j.psychres.2025.116446 Full text Ayahuasca Ketamine LSD Noribogaine +8

Measuring suicidal behavior in the era of rapid-acting antidepressants: A systematic review of ketamine studies.

Psychiatry Research June 1, 2025 Flávia Vieira, Ana Teresa Caliman-Fontes, Breno Souza-Marques et al.

Assessment measures for suicidal behavior range from depression scales to longer suicide-specific instruments. In this review, we systematically summarize and discuss the currently used instruments for assessing suicidal behavior in the context of ketamine and its enantiomers. We searched Medline/PubMed, Embase, and PsycINFO databases for ketamine (and its enantiomers) human studies exploring...

DOI: 10.1016/j.psychres.2025.116443 Full text Esketamine Major depressive disorder Mental health assessment Rapid-acting antidepressants +4

Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review

Psychiatry Research May 8, 2025 Noah Chisamore, Lee Phan, Roger S McIntyre et al. 7 citations

Psychedelics have re-emerged as promising treatments for mood disorders. The current model provides a moderate-to-high dose of a psychedelic agent (e.g., psilocybin) to reliably induce an altered state of consciousness. Unfortunately, the hallucinatory effects limit the treatment's potential scalability given patients' vulnerability and extensive monitoring costs, leading to growing interest in...

DOI: 10.1016/j.psychres.2025.116532 Psilocybin Anxiety Hallucinogen Mood +2

Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis.

Psychiatry Research May 1, 2025 Gerard Sanacora, Brian S. Barnett, Bo Hu et al. 2 citations

Previous studies have shown patient preference can have large effects on treatment adherence and patient satisfaction. However, the direct effects of matching treatment with patient preference on efficacy and safety outcomes remain unclear. We aimed to evaluate the effects of patient preference and preference-matching on efficacy, adverse events, and adherence to electroconvulsive therapy (ECT)...

DOI: 10.1016/j.psychres.2025.116411 Full text Patient preference matching Contextual Depression treatment Electroconvulsive therapy ect +2

Cannabis use and psychotic-like experiences: A systematic review of biological vulnerability, potency effects, and clinical trajectories.

Psychiatry Research April 1, 2025 Valerio Ricci, Stefania Chiappini, Giovanni Martinotti et al.

Epidemiological data have provided evidence that psychotic-like experiences (PLEs) occur in the general population without clinical impairment. According to the psychosis continuum hypothesis, PLEs are subject to multiple risk factors. This review synthesizes current research on biological, substance use-related, and environmental risk factors for PLEs in non-clinical populations....

DOI: 10.1016/j.psychres.2025.116496

A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.

Psychiatry Research March 1, 2025 Stephanie L. Haft, Amanda E. Downey, Marissa Raymond-Flesch et al. 22 citations

A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue has become a salient concern in studies of psychedelic-assisted psychotherapy (PAT), which is emerging as a promising mental health intervention. This systematic review evaluates the reporting, representation, and analysis of participant...

DOI: 10.1016/j.psychres.2025.116359 Full text Psychedelic research MDMA Therapy Systematic review Clinical diversity +2

Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.

Psychiatry Research March 1, 2025 Juliana Lima Constantino, Martijn Godschalk, Jens H van Dalfsen et al. 14 citations

Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression (TRD). Yet around 50% of the individuals with TRD do not respond to (es)ketamine. Elucidating predictors of response and remission could improve treatment outcomes at the individual level by defining subpopulations that are most likely to...

DOI: 10.1016/j.psychres.2025.116355 Full text Esketamine Major depressive disorder Treatment-resistant depression Psychopharmacology +5

Low-dose ketamine improved brain network integrity among patients with treatment-resistant depression and suicidal ideation.

Psychiatry Research March 1, 2025 Tung-Ping Su, Li-Kai Cheng, Pei-Chi Tu et al. 6 citations

Ketamine is a dissociative drug used for the treatment of depression. However, the neurofunctional mechanism underlying the antidepressant effect of ketamine remains unknown. According to previous research, low-dose ketamine affects large-scale brain networks, including default-mode and salient networks. A total of 43 patients with treatment-resistant depression (TRD) and suicidal ideation (SI)...

DOI: 10.1016/j.psychres.2025.116377 Full text Treatment-resistant depression Functional connectivity Graph theory Suicidal ideation +4

Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.

Psychiatry Research February 1, 2025 Damian Swieczkowski, Aleksander Kwaśny, Michal Pruc et al. 17 citations

Selecting the optimal dose of psilocybin for treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) is crucial for clinical development and regulatory approval. This meta-analysis evaluates psilocybin's efficacy and safety in treating MDD to determine the optimal dose and timing for clinical trials. A systematic review and Dose-Response Network Meta-Analysis (NMA) of...

DOI: 10.1016/j.psychres.2024.116337 Full text Major depressive disorder Treatment-resistant depression Psilocybin therapy Depression treatment +6

Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

Psychiatry Research February 1, 2025 Adam Bayes, Thanh Vinh Cao, Ana Rita Barreiros et al. 6 citations

Ketamine and its derivates (e.g. esketamine) are increasingly used in clinical settings for treatment-resistant depression (TRD). Ketamine can give rise to acute, cumulative and longer-term side effects (SEs) across a treatment course. The Ketamine Side Effect Tool (KSET) examines adverse effects though its length has affected feasibility for use in clinical settings. To estimate the frequency...

DOI: 10.1016/j.psychres.2024.116334 Full text Adverse events Side-effects Tolerability Depression therapy +4

Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: A case report

Psychiatry Research January 29, 2025 Felix Müller, Thomas Sauer, Corina Hänny et al. 11 citations

• A 60-year-old man with recurrent depression and history of delusions died after psilocybin-assisted therapy. • Psilocybin-triggered delusions and emotional dysregulation may have contributed. • Weak therapeutic alliance hindered assessment of patient's internal state. • Delusional symptoms may contraindicate psychedelic interventions. • This case emphasizes the need for thorough assessment...

DOI: 10.1016/j.psychres.2025.116381 Psilocybin Hallucinogen Telepathy Psychotherapist +1

Effect of intravenous ketamine on suicidality in adults with treatment-resistant depression: A real world effectiveness study.

Psychiatry Research 2025 David C J Chen-Li, Rodrigo B. Mansur, Joshua D. Di Vincenzo et al. 6 citations

Suicidal ideation is a significant symptom associated with mood disorders. Ketamine is an emerging treatment with rapid and robust antidepressant and antisuicidal effects observed in clinical trial populations. Herein we assessed the real-world effectiveness of ketamine in ameliorating suicidality. A retroactive chart analysis of 96 adult TRD patients that received treatment in a private...

DOI: 10.1016/j.psychres.2024.116282 Full text Antisuicidal effects Suicidal ideation Ketamine therapy Suicide prevention +2

Association of intravenous ketamine with change in depressive symptoms in a large integrated health care system.

Psychiatry Research 2025 Li Kevin J, Slama Natalie E, Chen Ingrid et al.

Racemic ketamine intravenous treatments (KIT) are widely used in community clinics for treatment resistant depression (TRD), but we lack studies on symptom improvement during standardized delivery to clinically complex patients with TRD. We aimed to assess depression symptom change for patients receiving standardized KIT for TRD in a large integrated health care delivery system relative to...

DOI: 10.1016/j.psychres.2024.116273 Full text Major depressive disorder Treatment-resistant depression Bipolar disorder Treatment resistant depression +3

Dissociative episodes and concurrent heart rate in patients with PTSD - An ecological momentary assessment.

Psychiatry Research 2025 Sarah Beutler-Traktovenko, Marcel Franz, Judith Daniels et al.

Dissociative symptoms are a frequent complication in posttraumatic stress disorders affecting about a third of all PTSD patients. While theoretical models predict a physiological hypoarousal during posttraumatic dissociations, empirical evidence is lacking. We addressed this by studying spontaneously occurring dissociative symptoms and related heart rate changes in an ecological momentary...

DOI: 10.1016/j.psychres.2024.116345 Full text

Change starts with the body: Interoceptive appreciation mediates the effect of mindfulness training on behavior change - an effect moderated by depression severity.

Psychiatry Research December 1, 2024 Zev Schuman-Olivier, Richa Gawande, Timothy B. Creedon et al. 10 citations

Mindfulness catalyzes health behavior change. Yet, interoception is dysregulated in depression, potentially impairing behavioral activation. We examined the mediating role of interoceptive appreciation, as measured by how much one trusts and listens to internal bodily signals, on behavior change. Primary care patients with depression, anxiety, or stress disorders related to chronic illness were...

DOI: 10.1016/j.psychres.2024.116230 Full text Depression Meditation Mindfulness Adherence +10

Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial.

Psychiatry Research December 1, 2024 Shampa Maji, Archana Mishra, Debadatta Mohapatra et al. 5 citations

Therapeutic latency, lack of response, and adverse drug reactions are major challenges in current treatment approaches for major depressive disorder (MDD). Following the success of ketamine, more clinical research on NMDA antagonists is needed for a safe and long-term therapy in MDD. Hence, this study was conducted to evaluate the efficacy and safety of adjunct dextromethorphan to SSRIs in MDD....

DOI: 10.1016/j.psychres.2024.116257 Full text Major depressive disorder Adjunct therapy Dextromethorphan Remission rate +6

Effects of mindfulness-based interventions (MBIs) on psychotic symptoms and psychological outcomes in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis.

Psychiatry Research December 1, 2024 Chuntana Reangsing, Sathit Wongsuraprakit, Sasinun Punsuwun et al. 5 citations

Mindfulness refers to the practice of consciously attending to the present moment without judgement. Although mindfulness-based intervention have been extensively researched. Less is known about the effect of this intervention on psychotic symptoms in patients with schizophrenia spectrum disorders. Thus, we synthesized the effects of mindfulness-based interventions (MBIs) on psychotic symptoms,...

DOI: 10.1016/j.psychres.2024.116272 Full text Meta-analysis Mindfulness-based interventions Schizophrenia

Investigating change in the ability to decentre and depressive symptomatology over the course of a six-month mindfulness-based intervention in patients with persistent depression.

Psychiatry Research November 1, 2024 Jonathan Hamilton, Thorsten Barnhofer 2 citations

Mindfulness-based interventions (MBIs) for depression use regular mindfulness practice as a means of helping patients build skills that allow them to respond more adaptively to negative mood. Although effects of practice are assumed to accumulate over time, little is known about the trajectories of change in skills and symptoms beyond the duration of standard eight-week interventions....

DOI: 10.1016/j.psychres.2024.116153 Full text Depression Mindfulness Blended intervention Online

Papers